Overview
Background
Professor Obermair is the Director of Queensland Centre for Gynaecological Cancer Research (QCGC Research). He is a Professor of Gynaecological Oncology since 2007, a Senior Medical Officer at Royal Brisbane & Women’s Hospital and a Visiting Medical Officer at St Andrews War Memorial Hospital and Buderim Private Hospital. He holds an Honorary title of Professor at UQ since 2006.
Professor Obermair is an internationally recognised leader in gynaecological oncology research and treatment and has lead the research team at QCGC Research since establishing it in 2003.
Availability
- Professor Andreas Obermair is:
- Available for supervision
Fields of research
Qualifications
- Doctoral Diploma of Medicine, International University Vienna
- Royal Australian and New Zealand College of Obstetricians and Gynaecologists, Royal Australian and New Zealand College of Obstetricians and Gynaecologists
Research interests
-
Clinical Trials
Decisions on cancer management ideally are based on the results of high-level evidence, obtained through clinical trials whenever possible. As a principle, a new (proposed better) intervention should be compared to the current standard treatment before being made available generally. Outside a clinical trial new treatments should not become available until evidence has become available to demonstrate superiority over the current standard treatment. Retrospective studies harbour the risk that biases influenced outcomes. At QCGC Research we engage in phase 2 and 3 clinical trials. In large phase trials, patients are allocated randomly to one of two or more interventions in order to minimise the risk of bias. Generally, patients treated within clinical trials have a better outcome compared to patients who are not treated in clinical trials. As the Director of Research Gynaecological Oncology I am currently involved in developing and managing clinical trials in gynaecological cancers.
-
Translational Research
The focus of QCGC Research's translational research program is the application of new technology (molecular, biochemical, imaging and surgical) to prevention, detection and therapy for gynaecological cancers.
-
Quality of Life Research
Cancer specialists are aware that not only the survival time but also the quality of life is a key factor in cancer treatment. This is especially important when two treatments are equally effective but cause different side-effects. My Quality-of-Life research focuses on ovarian, endometrial, cervical and vulval cancer. I wish to provide the best, most effective and modern treatment to my patients with least possible detriments to quality of life.
-
Minimally Invasive Surgery
In Australia, around 30,000 hysterectomies are conducted annually to treat uterine cancer and various benign gynaecological conditions. While open abdominal surgery may be necessary in around 10% of cases, evidence shows that less-invasive approaches, such as total laparoscopic hysterectomy (TLH) can achieve better outcomes for women at a lower overall cost to the health system. Yet, in Queensland, four of ten hysterectomies are still conducted by open abdominal surgery. Our own research has shown that many Australian surgeons are keen to adopt new techniques such as TLH, but that the lack of systematic training and mentoring opportunities is the main impediment to practice-change. Together with gynaecological surgical teams at hospitals and industry support we developed a prototype for system-level transformative practice change in gynaecological surgery.
Research impacts
Professor Obermair is an innovative and skilled gynaecologic oncologist, surgical teacher and consumer advocate. His international leadership and research impact was acknowledged in 2020 by the Australian community, when he was awarded an NHMRC Investigator Fellowship Level 2 (2021-25). The national impact of his research was recognised in 2017, when he was awarded Cancer Australia’s Jeannie Ferris Recognition Award (2017), for outstanding achievements in clinical practice and research. He is deeply engaged in consumer involvement and co-founded and serves on the Board of the Cherish Foundation, a consumer-focussed organisation that funds clinical research in better treatments for women with gynaecological cancers.
Works
Search Professor Andreas Obermair’s works on UQ eSpace
1995
Journal Article
The influence of obesity on the disease-free survival in primary breast cancer
Obermair, A, Kurz, C, Hanzal, E, BancherTodesca, D, Thoma, M, Bodisch, A, Kubista, E, Kyral, E, Kaider, A, Sevelda, P and Gitsch, G (1995). The influence of obesity on the disease-free survival in primary breast cancer. Anticancer Research, 15 (5B), 2265-2269.
1995
Journal Article
Serum Evaluation of Basic Fibroblast Growth-Factor in Cervical-Cancer Patients
Sliutz, G, Tempfer, C, Obermair, A, Reinthaller, A, Gitsch, G and Kainz, C (1995). Serum Evaluation of Basic Fibroblast Growth-Factor in Cervical-Cancer Patients. Cancer Letters, 94 (2), 227-231. doi: 10.1016/0304-3835(95)03853-O
1995
Journal Article
Microvessel Density and Vessel Invasion in Lymph-Node-Negative Breast-Cancer - Effect On Recurrence-Free Survival
Obermair, A, Kurz, C, Czerwenka, K, Thoma, M, Kaider, A, Wagner, T, Gitsch, G and Sevelda, P (1995). Microvessel Density and Vessel Invasion in Lymph-Node-Negative Breast-Cancer - Effect On Recurrence-Free Survival. International Journal of Cancer, 62 (2), 126-131. doi: 10.1002/ijc.2910620203
1995
Journal Article
Prognostic Value of Tumor Microvessel Density in Cancer of the Uterine Cervix Stage Ib to Iib
Kainz, C, Speiser, P, Wanner, C, Obermair, A, Tempfer, C, Sliutz, G, Reinthaller, A and Breitenecker, G (1995). Prognostic Value of Tumor Microvessel Density in Cancer of the Uterine Cervix Stage Ib to Iib. Anticancer Research, 15 (4), 1549-1551.
1995
Journal Article
Onycholysis of the finger and toenails following the application of high-dose oral etoposide (1250 mg/m2) given as 200- and 150-mg single doses from days 1-10 every 3 weeks
Obermair, A., Vavra, N., Kurz, C., Helmer, H., Sevelda, P. and Pehamberger, K. (1995). Onycholysis of the finger and toenails following the application of high-dose oral etoposide (1250 mg/m2) given as 200- and 150-mg single doses from days 1-10 every 3 weeks. Gynecologic Oncology, 57 (3)
1995
Journal Article
Untitled
Obermair, A, Vavra, N, Kurz, C, Helmer, H, Sevelda, P and Pehamberger, K (1995). Untitled. Gynecologic Oncology, 57 (3), 436-436.
1995
Journal Article
Tumor Microvessel Density in Breast-Cancer and its Influence On Recurrence-Free Survival - Reply
Obermair, A (1995). Tumor Microvessel Density in Breast-Cancer and its Influence On Recurrence-Free Survival - Reply. Chirurg, 66 (1), 77-77.
1995
Journal Article
Letter to the editor [1]
Obermair, A., Vavra, N., Kurz, C., Helmer, H., Sevelda, P. and Pehamberger, K. (1995). Letter to the editor [1]. Gynecologic Oncology, 57 (3), 436-438. doi: 10.1006/gyno.1995.1170
1994
Conference Publication
Delayed diagnosis of advanced endometrial carcinoma
Buxbaum, P, Obermair, A, Schreinerfrech, I, Kurz, C, Vavra, N and Sevelda, P (1994). Delayed diagnosis of advanced endometrial carcinoma. Annual Meeting of the Osterreichischen-Gesellschaft-fur-Gynakologie-und-Geburtshilfe, Bregenz Austria, Jun, 1994. BASEL: KARGER. doi: 10.1159/000272749
1994
Journal Article
Blood-Vessel Invasion in Breast-Cancer - a Comparison of Hematoxylin-Eosin Staining and Immunohistochemical Staining for Factor-Viii Antigen for Their Prognostic Value Concerning Tumor Recurrence
Obermair, A, Czerwenka, K, Kurz, C, Kaider, A and Sevelda, P (1994). Blood-Vessel Invasion in Breast-Cancer - a Comparison of Hematoxylin-Eosin Staining and Immunohistochemical Staining for Factor-Viii Antigen for Their Prognostic Value Concerning Tumor Recurrence. Deutsche Medizinische Wochenschrift, 119 (44), 1491-1496. doi: 10.1055/s-2008-1058863
1994
Conference Publication
Breast cancer in women under 35
Denison, U, Salzer, H, Obermair, A, Keil, M, Kurz, C, Vavra, N and Sevelda, P (1994). Breast cancer in women under 35. Annual Meeting of the Osterreichischen-Gesellschaft-fur-Gynakologie-und-Geburtshilfe, Bregenz Austria, Jun, 1994. BASEL: KARGER. doi: 10.1159/000272742
1994
Journal Article
Tumoral vascular density in breast tumors and their effect on recurrence-free survival Tumorale Gefässdichte bei Mammatumoren und ihr Einfluss auf das rezidivfreie Uberleben
Obermair, A., Czerwenka, K., Kurz, C., Kaider, A. and Sevelda, P. (1994). Tumoral vascular density in breast tumors and their effect on recurrence-free survival Tumorale Gefässdichte bei Mammatumoren und ihr Einfluss auf das rezidivfreie Uberleben. Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen, 65 (7), 611-615.
1994
Journal Article
Tumoral Microvessel Density in Breast-Cancer and its Influence On Recurrence-Free Survival
Obermair, A, Czerwenka, K, Kurz, C, Kaider, A and Sevelda, P (1994). Tumoral Microvessel Density in Breast-Cancer and its Influence On Recurrence-Free Survival. Chirurg, 65 (7), 611-615.
1994
Journal Article
Ranking of the factor 'vascular invasion' for the prognosis of carcinoma of the breast DIE WERTIGKEIT DES FAKTORS 'GEFASSINVASION' FUR DIE PROGNOSE DES MAMMAKARZINOMS
Kurz, C., Obermair, A., Nagele, F., Czerwenka, K., Schemper, M., Kubista, E. and Sevelda, P. (1994). Ranking of the factor 'vascular invasion' for the prognosis of carcinoma of the breast DIE WERTIGKEIT DES FAKTORS 'GEFASSINVASION' FUR DIE PROGNOSE DES MAMMAKARZINOMS. Geburtshilfe und Frauenheilkunde, 54 (5), 295-299.
1994
Journal Article
Ranking of the Factor Vascular Invasion for the Prognosis of Carcinoma of the Breast
Kurz, C, Obermair, A, Nagele, F, Czerwenka, K, Schemper, M, Kubista, E and Sevelda, P (1994). Ranking of the Factor Vascular Invasion for the Prognosis of Carcinoma of the Breast. Geburtshilfe Und Frauenheilkunde, 54 (5), 295-299. doi: 10.1055/s-2007-1022843
1994
Journal Article
Thrombosis with Paclitaxel
Sevelda, P, Mayerhofer, K, Obermair, A, Stolzlechner, J and Kurz, C (1994). Thrombosis with Paclitaxel. Lancet, 343 (8899), 727-727. doi: 10.1016/S0140-6736(94)91602-0
1994
Journal Article
Influence of Tumoral Microvessel Density On the Recurrence-Free Survival in Human Breast-Cancer - Preliminary-Results
Obermair, A, Czerwenka, K, Kurz, C, Buxbaum, P, Schemper, M and Sevelda, P (1994). Influence of Tumoral Microvessel Density On the Recurrence-Free Survival in Human Breast-Cancer - Preliminary-Results. Onkologie, 17 (1), 44-49. doi: 10.1159/000218380
1994
Journal Article
Blood vessel invasion in breast cancer. A comparison of haematoxylin-eosin staining and immunohistochemical staining for factor VIII antigen for their prognostic value concerning tumour recurrence TUMORGEFASSINVASION BEIM MAMMAKARZINOM. HAMATOXYLIN-EOSIN- VERSUS IMMUNHISTOCHEMISCHE FARBUNG GEGEN FAKTOR-VIII-ANTIGEN
Obermair, A., Czerwenka, K., Kurz, C., Kaider, A. and Sevelda, P. (1994). Blood vessel invasion in breast cancer. A comparison of haematoxylin-eosin staining and immunohistochemical staining for factor VIII antigen for their prognostic value concerning tumour recurrence TUMORGEFASSINVASION BEIM MAMMAKARZINOM. HAMATOXYLIN-EOSIN- VERSUS IMMUNHISTOCHEMISCHE FARBUNG GEGEN FAKTOR-VIII-ANTIGEN. Deutsche Medizinische Wochenschrift, 119 (44), 1491-1496.
1993
Conference Publication
Hormone-Therapy Vs Chemotherapy Plus Hormone-Therapy in Patients with Hormone Receptor-Positive Breast-Cancer in Stage-I and Stage-II
Sevelda, P, Kurz, C, Obermair, A, Kubista, E and Salzer, H (1993). Hormone-Therapy Vs Chemotherapy Plus Hormone-Therapy in Patients with Hormone Receptor-Positive Breast-Cancer in Stage-I and Stage-II. 49th Meeting of the Deutschen-Gesellschaft-fur-Gynakologie-und-Geburtshilfe, Berlin Germany, Sep 08-12, 1992. NEW YORK: SPRINGER VERLAG. doi: 10.1007/BF02266224
1993
Journal Article
The importance of platinum dose intensity in treatment of epithelial ovarian cancer DIE BEDEUTUNG DER PLATINDOSISINTENSITAT IN DER BEHANDLUNG DES EPITHELIALEN OVARIALKARZINOMS
Sevelda, P., Kurz, C., Obermair, A., Vavra, N., Breitenecker, G., Czerwenka, K., Dittrich, C. and Salzer, H. (1993). The importance of platinum dose intensity in treatment of epithelial ovarian cancer DIE BEDEUTUNG DER PLATINDOSISINTENSITAT IN DER BEHANDLUNG DES EPITHELIALEN OVARIALKARZINOMS. Wiener Klinische Wochenschrift, 105 (24), 732-736.
Funding
Current funding
Past funding
Supervision
Availability
- Professor Andreas Obermair is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Available projects
-
Improving Quality of Survival for Women with Gynaecological Cancer
- Focus on improving quality of life, health & function during & after gynaecological cancer treatment, with a focus on biomarker research, implementation research and cancer survivorship.
Supervision history
Current supervision
-
Doctor Philosophy
Advanced methods for biomarker informed endometrial cancer
Principal Advisor
Other advisors: Dr Eva Baxter, Dr Zoe West, Professor Andrew Martin
-
Master Philosophy
Patterns of care in endometrial cancer management in Queensland: a retrospective analysis.
Principal Advisor
Other advisors: Dr Eva Baxter
-
Doctor Philosophy
Diet quality, lifestyle, and metabolic profiles in women with endometrial cancer and their impact on health-related outcomes
Associate Advisor
Other advisors: Professor Monika Janda
Completed supervision
-
2014
Doctor Philosophy
Hereditary endometrial cancer: Improving identification and referral of patients with suspected Lynch syndrome
Principal Advisor
Other advisors: Honorary Professor Amanda Spurdle, Associate Professor Lisa Fitzgerald
-
2008
Doctor Philosophy
Nutritional status of patients with gynaecological cancer -
Joint Principal Advisor
Other advisors: Emeritus Professor Geoffrey Cleghorn
-
2009
Doctor Philosophy
Biology of CA125 in ovarian cancer biology
Associate Advisor
Other advisors: Honorary Professor Michael McGuckin
Media
Enquiries
For media enquiries about Professor Andreas Obermair's areas of expertise, story ideas and help finding experts, contact our Media team: